The stock has fallen 32% over the past year, but recent gains and options market activity hint at a possible recovery. Positive MiniMed 780G study results reinforce product strength. The company is expanding into health tech with new diagnostics and wearables like Lingo, and increasing R&D in cardiovascular diagnostics. However, Goldman Sachs removed the stock from its conviction list, and the nutrition segment faces consumer spending sensitivity.